V

Vistin Pharma ASA
OSE:VISTN

Watchlist Manager
Vistin Pharma ASA
OSE:VISTN
Watchlist
Price: 24 NOK 1.69% Market Closed
Market Cap: 1.1B NOK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one VISTN stock under the Base Case scenario is 25.57 NOK. Compared to the current market price of 24 NOK, Vistin Pharma ASA is Undervalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VISTN Relative Value
Base Case
25.57 NOK
Undervaluation 6%
Relative Value
Price
V
Worst Case
Base Case
Best Case

Valuation Multiples

2.5
P/S
P/S
Price to Sales
2.5
vs History
65
vs Industry
44
Median 3Y
2.5
Median 5Y
2.6
Industry
2.4
More Details
17
P/E
P/E
Price to Earnings
17
vs History
58
vs Industry
27
Median 3Y
17.6
Median 5Y
17.4
Industry
20.6
More Details
10.7
P/OCF
P/OCF
Price to OCF
10.7
vs History
57
vs Industry
35
Median 3Y
11.4
Median 5Y
11.1
Industry
15.5
More Details
19.1
P/FCFE
P/FCFE
Price to FCFE
19.1
vs History
46
vs Industry
22
Median 3Y
18.8
Median 5Y
15.1
Industry
23
More Details
3.4
P/B
P/B
Price to Book Value
3.4
vs History
34
vs Industry
21
Median 3Y
3.3
Median 5Y
3.2
Industry
1.9
More Details
2.4
EV/S
EV/S
Enterprise Value to Sales
2.4
vs History
68
vs Industry
42
Median 3Y
2.5
Median 5Y
2.5
Industry
2.5
More Details
3.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.8
vs History
82
vs Industry
50
Median 3Y
4.2
Median 5Y
4.2
Industry
4.9
More Details
10.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.1
vs History
82
vs Industry
32
Median 3Y
11.6
Median 5Y
12.5
Industry
12.6
More Details
12.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.3
vs History
69
vs Industry
32
Median 3Y
12.6
Median 5Y
14.3
Industry
15.7
More Details
10.5
EV/OCF
EV/OCF
Enterprise Value to OCF
10.5
vs History
53
vs Industry
36
Median 3Y
11.1
Median 5Y
10.4
Industry
14
More Details
18.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.9
vs History
39
vs Industry
23
Median 3Y
18.5
Median 5Y
-2.9
Industry
17.7
More Details
2.8
EV/IC
EV/IC
Enterprise Value to IC
2.8
vs History
55
vs Industry
25
Median 3Y
2.7
Median 5Y
2.8
Industry
1.8
More Details

Multiples Across Competitors

VISTN Competitors Multiples
Vistin Pharma ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Vistin Pharma ASA
OSE:VISTN
1.1B NOK 2.5 17 10.1 12.3
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
NO
V
Vistin Pharma ASA
OSE:VISTN
Average P/E: 25.2
17
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
V
Vistin Pharma ASA
OSE:VISTN
Average EV/EBITDA: 395.3
10.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
45.9
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.2
9%
14
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
V
Vistin Pharma ASA
OSE:VISTN
Average EV/EBIT: 1 698.6
12.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
VISTN intrinsic value, competitors valuation, and company profile.
DCF Valuation
VISTN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VISTN stock valuation using valuation multiples.
Wall Street Estimates
VISTN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VISTN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 249,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.